Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Sudhir Vrundavandas Valia has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE Q3 results on Feb 12, 2016
Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 12, 2016, interalia, to consider and take on record the Unaudited Financial Results of the Company for the Third quarter and nine months ended December 31, 2015 (Q3).Further, window closure for trading by designated persons as per Insider Trading Rules of the Company will be from February 03, 2016 to February 16, 2016 (both days inclusive). Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Jayant Sanghvi has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE Update on Sale of CNS divisions of erstwhile Ranbaxy to Strides Shasun Limited (formerly known as Strides Arcolab Ltd) - Receipt of order from Competition Commission of India approving the proposed transaction
With reference to the earlier Press Release dated September 19, 2015, regarding Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy.Sun Pharmaceutical Industries Ltd has now informed BSE that the Company has, on January 21, 2016 received order under the Competition Act, 2002 from the Competition Commission of India (CCI) approving the proposed transaction.With this approval, all necessary regulatory approvals have been obtained. Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015
Sun Pharmaceutical Industries Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Sudhir V Valia has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE
Petition against Sun Pharma for allegedly violating merger norms
Union claims Sun transferred and demoted some employees belonging to Ranbaxy after acquiring the firm Sun Pharmaceutical: Not a health scare
Troubles with the Halol plant and the Ranbaxy merger should pass Raising of funds by Sun Pharma Laboratories Ltd
Sun Pharmaceutical Industries Ltd has informed BSE that Sun Pharma Laboratories Limited, a wholly-owned subsidiary of the Company, has raised, on Private Placement Basis, Rs. 1000,00,00,000/- (Rupees One Thousand Crores only) by allotment of 10,000 (Ten Thousand) (ICRA) AAA / Stable Outlook Rated Unsecured Redeemable Non-Convertible Debentures of a face value of Rs. 10,00,000/- (Rupees Ten Lakh only) each to be listed on BSE Ltd under two series... Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Sudhir V Valia has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE